Market Overview

Agenus to Acquire Privately Held 4-Antibody AG for $10M in Stock

Agenus
(NASDAQ: AGEN) today
announced that it has entered into a definitive agreement to acquire
4-Antibody AG, a private European-based biopharmaceutical company.
4-Antibody has a technology platform for the rapid discovery and
optimization of fully-human antibodies against a wide array of molecular
targets of interest. These targets include checkpoint molecules that
regulate immune response to cancers and other diseases. The company has
multiple preclinical immune checkpoint antibody programs targeting
numerous checkpoint molecules, including GITR
and OX40,
as well as four additional undisclosed checkpoint programs. These
checkpoint programs are being pursued through a strategic collaboration

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Related Articles (AGEN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional